BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Heart failure (HF) may be considered as the fatal finishing line of all cardiovascular
disorders. Despite advances in the understanding and treatment, it still has a poor …

Although substantial improvements have been made in majority of cardiac disorders, heart
failure (HF) remains a major health problem, with both increasing incidence and prevalence …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

BACKGROUND Heart failure (HF) is a complex syndrome with an enormous societal burden
in terms of cost and morbidity and mortality. Natriuretic peptide (NP) testing is now widely …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …

Background: Heart failure (HF) is a devastating disease with increasing prevalence in
elderly populations. One-half of all patients die within 5 years of diagnosis. The annual cost …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

The spectrum of heart failure biomarkers and their potential clinical applications continues to
grow. Ongoing research on multimarker strategies will likely identify biomarker combinations …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …